The Eluvia drugeluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL substudy

The Eluvia drug-eluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL sub-study

MARLBOROUGH, Mass. (November 6, 2018) — Boston Scientific (NYSE: BSX) today announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia™ Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.

More From BioPortfolio on "The Eluvia drug-eluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL sub-study"